Caplacizumab resistance in immune thrombotic thrombocytopenic purpura (iTTP) associated with VWF A1 domain missense variant
Journal of Thrombosis and Haemostasis · 2026
DOI: 10.1016/j.jtha.2026.01.023 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Mari Thomas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, University College London Hospital, London, United Kingdom; Haematology Theme, National Institute for Health Research Biom…. Hauptthemen laut MEDLINE: von Willebrand Factor, Mutation, Missense, Purpura, Thrombotic Thrombocytopenic, Drug Resistance.
Abstract (Originalsprache)
Caplacizumab has been shown to reduce time to platelet normalization, reduce thrombotic thrombocytopenic purpura (TTP) exacerbations, and prevent refractory acute disease. We report the first case of caplacizumab "resistance" in a patient with immune TTP with a failure of suppression of in vivo von Willebrand factor (VWF) activity by the drug and persistence of VWF-mediated platelet capture in a flow-based in vitro assay. Genetic analysis revealed a missense variant, P1266L, in exon 28 of the VWF gene that affects the A1-domain binding site of glycoprotein Ib, but it is associated with normal platelet counts and the missense variant V1279I. Failure of caplacizumab therapy resulting in TTP exacerbation or relapse has to date been related to premature stopping of therapy associated with severe ADAMTS-13 (adisintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) deficiency. This case presents a previously unreported phenomenon involving a VWF variant that affects the A1 domain at the caplacizumab-binding site, impairing its effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, University College London Hospital, London, United Kingdom; Haematology Theme, National Institute for Health Research Biomedical Research Centre, University College London Hospitals/University…
- Institute of Cardiovascular Science, University College London, London, United Kingdom.
- Special Coagulation, Health Services Laboratories, London, United Kingdom.
Zitieren
APA
Thomas, M., Buckle, I., Constantinescu-Bercu, A., De Groot, R., McCann, S., & Scully, M. (2026). Caplacizumab resistance in immune thrombotic thrombocytopenic purpura (iTTP) associated with VWF A1 domain missense variant. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.01.023
Vancouver
Thomas M, Buckle I, Constantinescu-Bercu A, De Groot R, McCann S, Scully M. Caplacizumab resistance in immune thrombotic thrombocytopenic purpura (iTTP) associated with VWF A1 domain missense variant. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.01.023
BibTeX
@article{Thomas2026,
author = {Thomas, Mari and Buckle, Imogen and Constantinescu-Bercu, Adela and De Groot, Rens and McCann, Sabina and Scully, Marie},
title = {Caplacizumab resistance in immune thrombotic thrombocytopenic purpura (iTTP) associated with VWF A1 domain missense variant},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.jtha.2026.01.023}
}
EUVIMED